由亲和力成熟的可变结构域重复序列组成的单链蛋白对多种葡萄球菌超抗原的中和作用。
Neutralization of multiple staphylococcal superantigens by a single-chain protein consisting of affinity-matured, variable domain repeats.
作者信息
Yang Xi, Buonpane Rebecca A, Moza Beenu, Rahman A K M Nur-ur, Wang Ningyan, Schlievert Patrick M, McCormick John K, Sundberg Eric J, Kranz David M
机构信息
Department of Biochemistry, University of Illinois, Urbana, Illinois 61801, USA.
出版信息
J Infect Dis. 2008 Aug 1;198(3):344-8. doi: 10.1086/589776.
Abstract
Staphylococcus aureus secretes various toxins that act as superantigens by stimulating a large fraction of the host's T cells. Toxin binding to variable domains of T cell receptor beta chains (Vbeta) leads to massive release of inflammatory molecules and potentially to toxic shock syndrome (TSS). Previously, we generated soluble forms of different Vbeta domains with a high affinity for binding superantigens. However, a broader spectrum antagonist is required for the neutralization of multiple toxins. In the present study, we expressed Vbeta domains in tandem as a single-chain protein and neutralized the clinically important superantigens staphylococcal enterotoxin B and TSS toxin-1 with a single agent.
摘要
金黄色葡萄球菌分泌多种毒素，这些毒素作为超抗原，可刺激宿主的大部分T细胞。毒素与T细胞受体β链（Vβ）的可变域结合会导致炎症分子大量释放，并可能引发中毒性休克综合征（TSS）。此前，我们生成了对超抗原有高亲和力的不同Vβ域的可溶性形式。然而，中和多种毒素需要一种具有更广泛谱的拮抗剂。在本研究中，我们将Vβ域串联表达为单链蛋白，并用单一制剂中和了具有临床重要性的超抗原葡萄球菌肠毒素B和TSS毒素-1。
相似文献
1
Neutralization of multiple staphylococcal superantigens by a single-chain protein consisting of affinity-matured, variable domain repeats.
J Infect Dis. 2008 Aug 1;198(3):344-8. doi: 10.1086/589776.
2
Staphylococcus aureus superantigens elicit redundant and extensive human Vbeta patterns.
Infect Immun. 2009 May;77(5):2043-50. doi: 10.1128/IAI.01388-08. Epub 2009 Mar 2.
3
High affinity T cell receptors from yeast display libraries block T cell activation by superantigens.
J Mol Biol. 2001 Apr 13;307(5):1305-15. doi: 10.1006/jmbi.2001.4560.
4
A quantitative real time PCR method to analyze T cell receptor Vbeta subgroup expansion by staphylococcal superantigens.
J Transl Med. 2010 Jan 13;8:2. doi: 10.1186/1479-5876-8-2.
5
Soluble T cell receptor Vβ domains engineered for high-affinity binding to staphylococcal or streptococcal superantigens.
Toxins (Basel). 2014 Jan 28;6(2):556-74. doi: 10.3390/toxins6020556.
6
Staphylococcal toxin-induced T cell proliferation in atopic eczema correlates with increased use of superantigen-reactive Vbeta-chains in cutaneous lymphocyte-associated antigen (CLA)-positive lymphocytes.
Clin Exp Immunol. 2000 Aug;121(2):181-6. doi: 10.1046/j.1365-2249.2000.01270.x.
7
Immune response to staphylococcal superantigens.
Immunol Res. 1999;20(2):163-73. doi: 10.1007/BF02786471.
8
Human scFvs That Counteract Bioactivities of Staphylococcus aureus TSST-1.
Toxins (Basel). 2017 Feb 17;9(2):50. doi: 10.3390/toxins9020050.
9
The alpha 1 domain of the HLA-DR molecule is essential for high-affinity binding of the toxic shock syndrome toxin-1.
Nature. 1990 Aug 2;346(6283):474-6. doi: 10.1038/346474a0.
10
Staphylococcal enterotoxin-like toxins U2 and V, two new staphylococcal superantigens arising from recombination within the enterotoxin gene cluster.
Infect Immun. 2006 Aug;74(8):4724-34. doi: 10.1128/IAI.00132-06.
引用本文的文献
1
Sepsis: mechanisms of bacterial injury to the patient.
Scand J Trauma Resusc Emerg Med. 2019 Feb 14;27(1):19. doi: 10.1186/s13049-019-0596-4.
2
Toxins as biological weapons for terror-characteristics, challenges and medical countermeasures: a mini-review.
Disaster Mil Med. 2016 Apr 29;2:7. doi: 10.1186/s40696-016-0017-4. eCollection 2016.
3
Targeting Staphylococcus aureus Toxins: A Potential form of Anti-Virulence Therapy.
Toxins (Basel). 2016 Mar 15;8(3):72. doi: 10.3390/toxins8030072.
4
Soluble T cell receptor Vβ domains engineered for high-affinity binding to staphylococcal or streptococcal superantigens.
Toxins (Basel). 2014 Jan 28;6(2):556-74. doi: 10.3390/toxins6020556.
5
Staphylococcal Enterotoxin B-specific monoclonal antibody 20B1 successfully treats diverse Staphylococcus aureus infections.
J Infect Dis. 2013 Dec 15;208(12):2058-66. doi: 10.1093/infdis/jit421. Epub 2013 Aug 6.
6
Staphylococcal and streptococcal superantigen exotoxins.
Clin Microbiol Rev. 2013 Jul;26(3):422-47. doi: 10.1128/CMR.00104-12.
7
Staphylococcal enterotoxins.
Toxins (Basel). 2010 Aug;2(8):2177-97. doi: 10.3390/toxins2082177. Epub 2010 Aug 18.
8
Atopic dermatitis: a disease of altered skin barrier and immune dysregulation.
Immunol Rev. 2011 Jul;242(1):233-46. doi: 10.1111/j.1600-065X.2011.01027.x.
9
New insights into the prevention of staphylococcal infections and toxic shock syndrome.
Expert Rev Clin Pharmacol. 2010 Nov 1;3(6):753-767. doi: 10.1586/ecp.10.121.
10
Generation and characterization of high affinity human monoclonal antibodies that neutralize staphylococcal enterotoxin B.
J Immune Based Ther Vaccines. 2010 Dec 21;8:9. doi: 10.1186/1476-8518-8-9.
本文引用的文献
1
Neutralization of staphylococcal enterotoxin B by soluble, high-affinity receptor antagonists.
Nat Med. 2007 Jun;13(6):725-9. doi: 10.1038/nm1584. Epub 2007 May 21.
2
Molecular basis of TCR selectivity, cross-reactivity, and allelic discrimination by a bacterial superantigen: integrative functional and energetic mapping of the SpeC-Vbeta2.1 molecular interface.
J Immunol. 2006 Dec 15;177(12):8595-603. doi: 10.4049/jimmunol.177.12.8595.
3
Characterization of T cell receptors engineered for high affinity against toxic shock syndrome toxin-1.
J Mol Biol. 2005 Oct 21;353(2):308-21. doi: 10.1016/j.jmb.2005.08.041.
4
Engineered antibody fragments and the rise of single domains.
Nat Biotechnol. 2005 Sep;23(9):1126-36. doi: 10.1038/nbt1142.
5
The evolving field of biodefence: therapeutic developments and diagnostics.
Nat Rev Drug Discov. 2005 Apr;4(4):281-97. doi: 10.1038/nrd1694.
6
Domain antibodies: proteins for therapy.
Trends Biotechnol. 2003 Nov;21(11):484-90. doi: 10.1016/j.tibtech.2003.08.007.
7
Generation of protective immunity by inactivated recombinant staphylococcal enterotoxin B vaccine in nonhuman primates and identification of correlates of immunity.
Clin Immunol. 2003 Jul;108(1):51-9. doi: 10.1016/s1521-6616(03)00066-4.
8
Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation.
Immunity. 2003 Feb;18(2):255-64. doi: 10.1016/s1074-7613(03)00019-0.
9
Toxic shock syndrome and bacterial superantigens: an update.
Annu Rev Microbiol. 2001;55:77-104. doi: 10.1146/annurev.micro.55.1.77.
10
Inhibition of staphylococcal enterotoxin B-induced lymphocyte proliferation and tumor necrosis factor alpha secretion by MAb5, an anti-toxic shock syndrome toxin 1 monoclonal antibody.
Infect Immun. 2000 Jun;68(6):3261-8. doi: 10.1128/IAI.68.6.3261-3268.2000.
Zotero 插件